RAD51D’s loss-of-function mutation is an inclusion criterion for trials evaluating the effectiveness of Rucaparib in ovarian cancer [30] or prostate cancer [31], Talazoparib in HER2-negative BC [32], and Niraparib in pancreatic cancer [33]. The gene discussed is RAD51D; the disease is ovarian cancer.